Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma

Andrea Di Cristofori, Giorgio Carrabba, Giordano Lanfranchi, Claudia Menghetti, Paolo Rampini, Manuela Caroli

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol. Second-line treatments for GBM have not been yet defined. Tamoxifen is an anti-estrogen molecule with anti-neoplastic effects whose role is under investigation. tamoxifen is generally well tolerated but thromboembolic complications have been reported. In this study, we report our experience on the administration of tamoxifen plus dosedense TMZ in patients with recurrent GBM. Patients and Methods: All patients underwent surgical resection of GBM and completed concomitant RT and TMZ. Eligibility criteria also included evidence of GBM recurrence and good general conditions [Karnofsky Performance Score (KPS) >70] at recurrence. Patients with rapidly progressive disease, clearly unfavorable prognosis, or history of deep-venous thrombosis were excluded. The second-line treatment consisted of dosedense TMZ (75-150 mg/m2 one week on/ one week off) plus daily tamoxifen (80 mg/m2). Follow-up was performed with contrast-enhanced brain Magnetic Resonance Imaging (MRI) every three months. Results: Thirty-two patients (18 males, 14 females; median age 57 years) with GBM relapse were included. Median overall survival time (OS) and time to tumor progression after recurrence (TTP-2) were 17.5 and 7 months, respectively. Interestingly, no differences in OS and TTP-2 were noted in GBM between those with methylated and unmethylated MGMT. None of the patients had complications related to TMZ plus tamoxifen administration. Conclusion: The combinatorial administration of tamoxifen and TMZ appeared to be well-tolerated, and potentially effective in increasing the efficacy of dose-dense TMZ schedule as a second-line therapeutic strategy.

Original languageEnglish
Pages (from-to)3383-3390
Number of pages8
JournalAnticancer Research
Volume33
Issue number8
Publication statusPublished - Aug 2013

Fingerprint

temozolomide
Tamoxifen
Glioblastoma
Recurrence
Radiotherapy
Survival
Standard of Care
Venous Thrombosis
Appointments and Schedules
Estrogens
Therapeutics

Keywords

  • Dose-dense schedule
  • Glioblastoma
  • Tamoxifen
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. / Di Cristofori, Andrea; Carrabba, Giorgio; Lanfranchi, Giordano; Menghetti, Claudia; Rampini, Paolo; Caroli, Manuela.

In: Anticancer Research, Vol. 33, No. 8, 08.2013, p. 3383-3390.

Research output: Contribution to journalArticle

Di Cristofori, A, Carrabba, G, Lanfranchi, G, Menghetti, C, Rampini, P & Caroli, M 2013, 'Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma', Anticancer Research, vol. 33, no. 8, pp. 3383-3390.
Di Cristofori, Andrea ; Carrabba, Giorgio ; Lanfranchi, Giordano ; Menghetti, Claudia ; Rampini, Paolo ; Caroli, Manuela. / Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. In: Anticancer Research. 2013 ; Vol. 33, No. 8. pp. 3383-3390.
@article{9271f75d642d4ca8bc953cdeee141d9c,
title = "Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma",
abstract = "Background: The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol. Second-line treatments for GBM have not been yet defined. Tamoxifen is an anti-estrogen molecule with anti-neoplastic effects whose role is under investigation. tamoxifen is generally well tolerated but thromboembolic complications have been reported. In this study, we report our experience on the administration of tamoxifen plus dosedense TMZ in patients with recurrent GBM. Patients and Methods: All patients underwent surgical resection of GBM and completed concomitant RT and TMZ. Eligibility criteria also included evidence of GBM recurrence and good general conditions [Karnofsky Performance Score (KPS) >70] at recurrence. Patients with rapidly progressive disease, clearly unfavorable prognosis, or history of deep-venous thrombosis were excluded. The second-line treatment consisted of dosedense TMZ (75-150 mg/m2 one week on/ one week off) plus daily tamoxifen (80 mg/m2). Follow-up was performed with contrast-enhanced brain Magnetic Resonance Imaging (MRI) every three months. Results: Thirty-two patients (18 males, 14 females; median age 57 years) with GBM relapse were included. Median overall survival time (OS) and time to tumor progression after recurrence (TTP-2) were 17.5 and 7 months, respectively. Interestingly, no differences in OS and TTP-2 were noted in GBM between those with methylated and unmethylated MGMT. None of the patients had complications related to TMZ plus tamoxifen administration. Conclusion: The combinatorial administration of tamoxifen and TMZ appeared to be well-tolerated, and potentially effective in increasing the efficacy of dose-dense TMZ schedule as a second-line therapeutic strategy.",
keywords = "Dose-dense schedule, Glioblastoma, Tamoxifen, Temozolomide",
author = "{Di Cristofori}, Andrea and Giorgio Carrabba and Giordano Lanfranchi and Claudia Menghetti and Paolo Rampini and Manuela Caroli",
year = "2013",
month = "8",
language = "English",
volume = "33",
pages = "3383--3390",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma

AU - Di Cristofori, Andrea

AU - Carrabba, Giorgio

AU - Lanfranchi, Giordano

AU - Menghetti, Claudia

AU - Rampini, Paolo

AU - Caroli, Manuela

PY - 2013/8

Y1 - 2013/8

N2 - Background: The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol. Second-line treatments for GBM have not been yet defined. Tamoxifen is an anti-estrogen molecule with anti-neoplastic effects whose role is under investigation. tamoxifen is generally well tolerated but thromboembolic complications have been reported. In this study, we report our experience on the administration of tamoxifen plus dosedense TMZ in patients with recurrent GBM. Patients and Methods: All patients underwent surgical resection of GBM and completed concomitant RT and TMZ. Eligibility criteria also included evidence of GBM recurrence and good general conditions [Karnofsky Performance Score (KPS) >70] at recurrence. Patients with rapidly progressive disease, clearly unfavorable prognosis, or history of deep-venous thrombosis were excluded. The second-line treatment consisted of dosedense TMZ (75-150 mg/m2 one week on/ one week off) plus daily tamoxifen (80 mg/m2). Follow-up was performed with contrast-enhanced brain Magnetic Resonance Imaging (MRI) every three months. Results: Thirty-two patients (18 males, 14 females; median age 57 years) with GBM relapse were included. Median overall survival time (OS) and time to tumor progression after recurrence (TTP-2) were 17.5 and 7 months, respectively. Interestingly, no differences in OS and TTP-2 were noted in GBM between those with methylated and unmethylated MGMT. None of the patients had complications related to TMZ plus tamoxifen administration. Conclusion: The combinatorial administration of tamoxifen and TMZ appeared to be well-tolerated, and potentially effective in increasing the efficacy of dose-dense TMZ schedule as a second-line therapeutic strategy.

AB - Background: The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol. Second-line treatments for GBM have not been yet defined. Tamoxifen is an anti-estrogen molecule with anti-neoplastic effects whose role is under investigation. tamoxifen is generally well tolerated but thromboembolic complications have been reported. In this study, we report our experience on the administration of tamoxifen plus dosedense TMZ in patients with recurrent GBM. Patients and Methods: All patients underwent surgical resection of GBM and completed concomitant RT and TMZ. Eligibility criteria also included evidence of GBM recurrence and good general conditions [Karnofsky Performance Score (KPS) >70] at recurrence. Patients with rapidly progressive disease, clearly unfavorable prognosis, or history of deep-venous thrombosis were excluded. The second-line treatment consisted of dosedense TMZ (75-150 mg/m2 one week on/ one week off) plus daily tamoxifen (80 mg/m2). Follow-up was performed with contrast-enhanced brain Magnetic Resonance Imaging (MRI) every three months. Results: Thirty-two patients (18 males, 14 females; median age 57 years) with GBM relapse were included. Median overall survival time (OS) and time to tumor progression after recurrence (TTP-2) were 17.5 and 7 months, respectively. Interestingly, no differences in OS and TTP-2 were noted in GBM between those with methylated and unmethylated MGMT. None of the patients had complications related to TMZ plus tamoxifen administration. Conclusion: The combinatorial administration of tamoxifen and TMZ appeared to be well-tolerated, and potentially effective in increasing the efficacy of dose-dense TMZ schedule as a second-line therapeutic strategy.

KW - Dose-dense schedule

KW - Glioblastoma

KW - Tamoxifen

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84883391918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883391918&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 3383

EP - 3390

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -